株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の遺伝性検査市場:疾患タイプ、地域別 - 市場規模、シェア、動向 、セグメント別予測(2020年~2026年)

Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2020 - 2026

発行 Grand View Research, Inc. 商品コード 927117
出版日 ページ情報 英文 276 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.59円で換算しております。
世界の遺伝性検査市場:疾患タイプ、地域別 - 市場規模、シェア、動向 、セグメント別予測(2020年~2026年) Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2020 - 2026
出版日: 2020年02月28日 ページ情報: 英文 276 Pages
概要

世界の遺伝性検査市場は、予測期間中に6.3%のCAGRで拡大する見通しで、2026年には89億米ドルに達すると予測されています。同市場を牽引している主な要因は、シーケンシングのコストの低下と低価格での遺伝子検査の入手可能性です。 また、ゲノミクスバリューチェーンにおけるニッチおよび断片化されたポイントソリューション、シーケンス、分析、解釈、集約、および市場の可用性は、予測期間中の市場成長を促進すると見込まれています。

当レポートは世界の遺伝性検査市場について調査しており、市場動向、戦略分析、規制の見通し、疾患タイプ・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • 情報またはデータ分析
  • 市場の定式化と検証
  • 市場の範囲とセグメントの定義
  • 市場モデル

第2章 エグゼクティブサマリー

  • 市場のスナップショット

第3章 市場変数、動向、および範囲

  • 市場のセグメンテーションと範囲
  • 市場力学
  • 産業ピラミッド分析
  • 技術マッピング
  • 規制の見通し:地域別
  • 普及と成長見通しのマッピング:疾病タイプ
  • 要因別:SWOT分析(政治的、法的、経済的、技術的)
  • 産業分析:ポーターのファイブフォース分析

第4章 市場分析:疾患タイプ別

  • 市場動向分析
  • 遺伝性癌検査
    • 肺癌
    • 乳癌
    • 大腸癌
    • 子宮頸癌
    • 卵巣癌
    • 前立腺癌
    • 胃癌
    • 黒色腫
    • 肉腫
    • 子宮癌
    • 膵臓癌
    • その他
  • 遺伝性非癌検査
    • 遺伝性の非癌遺伝子検査
    • 新生児の遺伝子スクリーニング
    • 着床前遺伝子診断・スクリーニング(PGD / PGS)
    • 非侵襲的出生前検査(NIPT)・保因者スクリーニング

第5章 市場分析:疾患タイプ別

  • 市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ(MEA)

第6章 競合情勢

  • 主な取引、アライアンス戦略分析
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 Product mapping for hereditary cancer tests
  • TABLE 2 DNA sequencing costs over the past decade
  • TABLE 3 Global incidence rate of genetic disorders
  • TABLE 4 Technology landscape for NIPT tests
  • TABLE 5 Comparison of other technologies
  • TABLE 6 Countries that prescribe mandatory medical supervision & restriction for genetic tests
  • TABLE 7 Susceptibility genes and their prevalence in hereditary ovarian syndromes
  • TABLE 8 Various NGS tests for hereditary prostate cancer
  • TABLE 9 Genetic testing scenario for patients/families affected by inherited cardiac disease
  • TABLE 10 Financial solutions for PGT:
  • TABLE 11 Commercial landscape of NIPT for fetal aneuploidy in the U.S.
  • TABLE 12 North America hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 13 North America hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 14 North America hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 15 North America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 16 U.S. hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 17 U.S. hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 18 U.S. hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 19 U.S. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 20 Canada hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 21 Canada hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 22 Canada hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 23 Canada hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 24 Europe hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 25 Europe hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 26 Europe hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 27 Europe hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 28 U.K. hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 29 U.K. hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 30 U.K. hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 31 U.K. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 32 Germany hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 33 Germany hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 34 Germany hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 35 Germany hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 36 France hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 37 France hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 38 France hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 39 France hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 40 Spain hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 41 Spain hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 42 Spain hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 43 Spain hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 44 Italy hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 45 Italy hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 46 Italy hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 47 Italy hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 48 Netherlands hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 49 Netherlands hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 50 Netherlands hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 51 Netherlands hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 52 Asia Pacific hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 53 Asia Pacific hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 54 Asia Pacific hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 55 Asia Pacific hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 56 China hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 57 China hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 58 China hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 59 China hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 60 Japan hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 61 Japan hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 62 Japan hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 63 Japan hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 64 India hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 65 India hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 66 India hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 67 India hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 68 South Korea hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 69 South Korea hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 70 South Korea hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 71 South Korea hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 72 Australia hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 73 Australia hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 74 Australia hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 75 Australia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 76 Singapore hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 77 Singapore hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 78 Singapore hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 79 Singapore hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 80 South East Asia hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 81 South East Asia hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 82 South East Asia hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 83 South East Asia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 84 Latin America hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 85 Latin America hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 86 Latin America hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 87 Latin America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 88 Brazil hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 89 Brazil hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 90 Brazil hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 91 Brazil hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 92 MEA hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 93 MEA hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 94 MEA hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 95 MEA hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)
  • TABLE 96 South Africa hereditary testing market estimates & forecasts, by disease type, 2015 - 2026 (USD Million)
  • TABLE 97 South Africa hereditary cancer testing market estimates & forecasts, by type, 2015 - 2026 (USD Million)
  • TABLE 98 South Africa hereditary non-cancer testing market estimates & forecasts, by test type, 2015 - 2026 (USD Million)
  • TABLE 99 South Africa hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value-chain-based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market model for hereditary testing market
  • FIG. 8 Commodity flow approach for volume estimates
  • FIG. 9 Commodity flow approach for revenue estimates
  • FIG. 10 Cause of cervical cancer
  • FIG. 11 Commodity flow analysis for newborn genetic screening market
  • FIG. 12 Newborn landscape, 2019
  • FIG. 13 Number of newborns
  • FIG. 14 Commodity flow approach for preimplantation genetic testing Market
  • FIG. 15 Number of PGT cycle, the U.S.
  • FIG. 16 Commodity flow approach for NIPT & carrier screening market
  • FIG. 17 Penetration of NIPT market, U.S.
  • FIG. 18 Outcome of Non-invasive Parental Screening (NIPS)
  • FIG. 19 Market summary (2019, USD Millions)
  • FIG. 20 Market segmentation & scope
  • FIG. 21 Market trends & outlook
  • FIG. 22 Market driver relevance analysis (Current & future impact)
  • FIG. 23 Coverage for newborn metabolic screening in New Zealand
  • FIG. 24 Women's health diagnostics: Competitive landscape
  • FIG. 25 Genetic testing registry, number of registered labs globally
  • FIG. 26 Number of registered labs, by country, 2018 (%)
  • FIG. 27 Market restraints relevance analysis (Current & future impact)
  • FIG. 28 Overbilling issues faced by insurance providers for genetic testing
  • FIG. 29 Reduction in amniocentesis and CVS procedures, with increase in NIPTs
  • FIG. 30 Consumer genomics: Value chain analysis
  • FIG. 31 Industry pyramid analysis
  • FIG. 32 Technology comparison
  • FIG. 33 Steps to be taken by payers for reimbursement of hereditary tests
  • FIG. 34 Penetration & growth prospect mapping, disease type, 2019
  • FIG. 35 SWOT analysis, by factor (Political & legal, economic, and technological)
  • FIG. 36 Porter's Five Forces Analysis
  • FIG. 37 Global hereditary testing market: Disease type outlook key takeaways
  • FIG. 38 Global hereditary testing market: Disease type movement analysis
  • FIG. 39 Global hereditary cancer testing market, 2015 - 2026 (USD Million)
  • FIG. 40 Global hereditary cancer testing market for lung cancer, 2015 - 2026 (USD Million)
  • FIG. 41 New cases of breast cancer in the U.S., 2014-2017
  • FIG. 42 Global hereditary cancer testing market for breast cancer market, 2015 - 2026 (USD Million)
  • FIG. 43 Estimated new cases of colorectal cancer in the U.S., 2014-2017
  • FIG. 44 Common types of hereditary colon cancer
  • FIG. 45 Global hereditary cancer testing market for colorectal cancer, 2015 - 2026 (USD Million)
  • FIG. 46 Global hereditary cancer testing market for cervical cancer, 2015 - 2026 (USD Million)
  • FIG. 47 Global hereditary cancer testing market for ovarian cancer, 2015 - 2026 (USD Million)
  • FIG. 48 Global hereditary cancer testing market for prostate cancer, 2015 - 2026 (USD Million)
  • FIG. 49 Global hereditary cancer testing market for stomach/gastric cancer, 2015 - 2026 (USD Million)
  • FIG. 50 Global hereditary cancer testing market for melanoma, 2015 - 2026 (USD Million)
  • FIG. 51 Global hereditary cancer testing market for sarcoma, 2015 - 2026 (USD Million)
  • FIG. 52 Global hereditary cancer testing market for uterine cancer, 2015 - 2026 (USD Million)
  • FIG. 53 Global hereditary cancer testing market for pancreatic cancer, 2015 - 2026 (USD Million)
  • FIG. 54 Global hereditary cancer testing market for other cancers, 2015 - 2026 (USD Million)
  • FIG. 55 Global hereditary non-cancer testing market, 2015 - 2026 (USD Million)
  • FIG. 56 Global hereditary non-cancer genetic tests market, 2015 - 2026 (USD Million)
  • FIG. 57 Global hereditary genetic tests market for cardiac diseases, 2015 - 2026 (USD Million)
  • FIG. 58 Global hereditary genetic tests market for rare diseases, 2015 - 2026 (USD Million)
  • FIG. 59 Global hereditary genetic tests market for other diseases, 2015 - 2026 (USD Million)
  • FIG. 60 Global newborn genetic screening market for inherited conditions, 2015 - 2026 (USD Million)
  • FIG. 61 Global PGD/PGS market for inherited conditions, 2015 - 2026 (USD Million)
  • FIG. 62 Global non-invasive prenatal testing (NIPT) & carrier screening tests market for inherited conditions, 2015 - 2026 (USD Million)
  • FIG. 63 Regional market place: Key takeaway
  • FIG. 64 Hereditary testing market regional outlook, 2019 & 2026
  • FIG. 65 North America hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 66 SCID newborn screening timeline in the U.S.
  • FIG. 67 U.S. hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 68 Objectives of the Screen Project
  • FIG. 69 Canada hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 70 Europe hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 71 U.K. hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 72 Germany hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 73 France hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 74 Spain hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 75 Declining trend of Amniocenteses performed from 2007 to 2017 in Italy
  • FIG. 76 Italy hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 77 Netherlands hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 78 Asia Pacific hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 79 China hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 80 Japan hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 81 India hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 82 South Korea hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 83 Australia hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 84 Singapore hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 85 Crude birth rate in Southeast Asia 2018, by country
  • FIG. 86 South East Asia hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 87 Latin America hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 88 Brazil hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 89 MEA hereditary testing market, 2015 - 2026 (USD Million)
  • FIG. 90 South Africa hereditary testing market, 2015 - 2026 (USD Million)
目次
Product Code: GVR-4-68038-999-9

The global hereditary testing market size is expected to reach USD 8.9 billion by 2026, expanding at a CAGR of 6.3% over the forecast period, according to a new report by Grand View Research, Inc. Key factors driving the market are declining cost of sequencing and availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point-solutions across genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.

The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.

Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in June 2019, QIAGEN launched a new QIAseq Expanded Carrier Screening Panel, a novel Next-generation Sequencing (NGS) panel integrated with advanced bioinformatics solutions for rare and inherited diseases testing. Such ongoing developments in the market space are expected to boost revenue growth to a large extent in the coming years.

Further key findings from the report suggest:

  • A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer. This has led to increased hereditary testing market share of hereditary testing for cancer in 2019
  • Breast cancer testing segment has dominated the hereditary cancer testing market owing to its high penetration and increased inheritability
  • On the other hand, most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
  • Emergence of high-throughput sequencing has resulted in commercial availability of a significant number of sequencing assays for cardiomyopathies, thereby driving the cardiac diseases segment
  • Non-invasive Prenatal Testing (NIPT) and newborn genetic screening continue to witness lucrative growth due to increased adoption across the globe
  • Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in large share of these test types among the hereditary non-cancer testing segment
  • Europe and North America collectively accounted for nearly 70% of the revenue generated in 2019 owing to assisted reproductive technology space coupled with high penetration of newborn genetic screening
  • Myriad Genetics, Inc.; Quest Diagnostics Incorporated; Invitae Corporation; Illumina, Inc.; and Natera, Inc. are some of the major key players operating in the marketplace
  • These companies are engaged in securing regulatory approval in the emerging countries to expand their business footprint
  • A substantial number of diagnostic companies have collaborated with technology developers to obtain technology license and deliver high value services to their customers.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation
  • 1.4 Market Scope & Segment Definition
    • 1.4.1 Hereditary cancer testing
    • 1.4.2 Hereditary non-cancer testing
      • 1.4.2.1 Genetic tests
      • 1.4.2.2 Newborn genetic screening
      • 1.4.2.3 Preimplantation genetic diagnosis & screening
      • 1.4.2.4 Non-invasive Prenatal Testing (NIPT) & carrier screening tests
  • 1.5 Market Model
    • 1.5.1 Hereditary cancer testing market
      • 1.5.1.1 Market study
      • 1.5.1.1.1 Price case study
      • 1.5.1.1.2 Test provision study
      • 1.5.1.1.3 Market competition study
      • 1.5.1.1.4 Reimbursement study
      • 1.5.1.2 Product mapping by cancer type & company
    • 1.5.2 Hereditary non-cancer genetic testing market
      • 1.5.2.1 Newborn genetic screening market
      • 1.5.2.2 Preimplantation genetic testing market; NIPT & carrier screening market

Chapter 2 Executive Summary

  • 2.1 Market Snapshot (2019, USD Millions)

Chapter 3 Hereditary Testing Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Increase in sales and demand for DNA test kits
      • 3.2.1.2 Constantly developing commercial landscape of women's reproductive health
      • 3.2.1.3 Decline in sequencing cost & consequent expansion of genetic testing registry
    • 3.2.2 Market restraints analysis
      • 3.2.2.1 Ethical and clinical issues of DNA tests
      • 3.2.2.2 Regulatory challenges pertaining to use of DTC genetic tests
    • 3.2.3 Market opportunity analysis
      • 3.2.3.1 Increasing incidence of genetic diseases
      • 3.2.3.2 Presence of demand for early and noninvasive fetal testing procedures
      • 3.2.3.3 Introduction of fragmented point-solutions across the genomics value chain
  • 3.3 Industry Pyramid Analysis
  • 3.4 Technology Mapping
    • 3.4.1 PGS Technology Analysis
      • 3.4.1.1 aCGH
      • 3.4.1.2 NGS
      • 3.4.1.3 Others
      • 3.4.1.4 Introduction of technological advancements in cloud computing and data integration
  • 3.5 Regulatory Landscape, by Geography
    • 3.5.1 U.S.
    • 3.5.2 Europe
      • 3.5.2.1 Germany
    • 3.5.3 China
    • 3.5.4 Japan
  • 3.6 Penetration & Growth Prospect Mapping, Disease Type, 2019
  • 3.7 Hereditary Testing Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.8 Industry Analysis - Porter's

Chapter 4 Hereditary Testing Market: Disease Type Estimates & Trend Analysis

  • 4.1 Hereditary Testing Market: Disease Type Movement Analysis
  • 4.2 Hereditary Cancer Testing
    • 4.2.1 Global hereditary cancer testing market, 2015 - 2026 (USD Million)
    • 4.2.2 Lung cancer
      • 4.2.2.1 Global hereditary cancer testing market for lung cancer, 2015 - 2026 (USD Million)
    • 4.2.3 Breast cancer
      • 4.2.3.1 Global hereditary cancer testing market for breast cancer, 2015 - 2026 (USD Million)
    • 4.2.4 Colorectal cancer
      • 4.2.4.1 Global hereditary cancer testing market for colorectal cancer, 2015 - 2026 (USD Million)
    • 4.2.5 Cervical cancer
      • 4.2.5.1 Global hereditary cancer testing market for cervical cancer, 2015 - 2026 (USD Million)
    • 4.2.6 Ovarian cancer
      • 4.2.6.1 Global hereditary cancer testing market for ovarian cancer, 2015 - 2026 (USD Million)
    • 4.2.7 Prostate cancer
      • 4.2.7.1 Global hereditary cancer testing market for prostate cancer, 2015 - 2026 (USD Million)
    • 4.2.8 Stomach/gastric cancer
      • 4.2.8.1 Global hereditary cancer testing market for stomach/gastric cancer, 2015 - 2026 (USD Million)
    • 4.2.9 Melanoma
      • 4.2.9.1 Global hereditary cancer testing market for melanoma, 2015 - 2026 (USD Million)
    • 4.2.10 Sarcoma
      • 4.2.10.1 Global hereditary cancer testing market for sarcoma, 2015 - 2026 (USD Million)
    • 4.2.11 Uterine cancer
      • 4.2.11.1 Global hereditary cancer testing market for uterine cancer, 2015 - 2026 (USD Million)
    • 4.2.12 Pancreatic cancer
      • 4.2.12.1 Global hereditary cancer testing market for pancreatic cancer, 2015 - 2026 (USD Million)
    • 4.2.13 Other cancers
      • 4.2.13.1 Global hereditary cancer testing market for other cancers, 2015 - 2026 (USD Million)
  • 4.3 Hereditary Non-cancer Testing
    • 4.3.1 Global hereditary non-cancer testing market, 2015 - 2026 (USD Million)
    • 4.3.2 Hereditary non-cancer genetic testing
      • 4.3.2.1 Global hereditary non-cancer genetic testing market, 2015 - 2026 (USD Million)
      • 4.3.2.2 Hereditary genetic testing for cardiac disease
      • 4.3.2.2.1 Global hereditary genetic testing market for cardiac diseases, 2015 - 2026 (USD Million)
      • 4.3.2.3 Hereditary genetic testing for rare disease
      • 4.3.2.3.1 Global hereditary genetic testing market for rare diseases, 2015 - 2026 (USD Million)
      • 4.3.2.4 Hereditary genetic testing for other diseases
      • 4.3.2.4.1 Global hereditary genetic testing market for other diseases, 2015 - 2026 (USD Million)
    • 4.3.3 Newborn genetic screening
      • 4.3.3.1 Global newborn genetic screening market for inherited conditions, 2015 - 2026 (USD Million)
    • 4.3.4 Preimplantation Genetic Diagnosis & Screening (PGD/PGS)
      • 4.3.4.1 Global PGD/PGS market for inherited conditions, 2015 - 2026 (USD Million)
    • 4.3.5 Non-invasive prenatal testing (NIPT) & carrier screening
      • 4.3.5.1 Global non-invasive prenatal testing (NIPT) & carrier screening tests market for inherited conditions, 2015 - 2026 (USD Million)

Chapter 5 Hereditary Testing Market Categorization: Regional Estimates & Trend Analysis by Disease Type

  • 5.1 Hereditary Testing Market Share By Region, 2019 & 2026
  • 5.2 North America
    • 5.2.1 North America hereditary testing market, 2015 - 2026 (USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada hereditary testing market, by disease type, 2015 - 2026 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.3.2 U.K.
      • 5.3.2.1 U.K. hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Germany hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.3.4 France
      • 5.3.4.1 France hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.3.5 Spain
      • 5.3.5.1 Spain hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.3.6 Italy
      • 5.3.6.1 Italy hereditary testing market, by disease type, 2015 - 2026
    • 5.3.7 Netherlands
      • 5.3.7.1 Netherlands hereditary testing market, by disease type, 2015 - 2026 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.2 China
      • 5.4.2.1 China hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.3 Japan
      • 5.4.3.1 Japan hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.4 India
      • 5.4.4.1 India hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.5 South Korea
      • 5.4.5.1 South Korea hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.6 Australia
      • 5.4.6.1 Australia hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.4.7 Singapore
      • 5.4.7.1 Singapore hereditary testing market, by disease type, 2015
    • 5.4.8 South East Asia
      • 5.4.8.1 South East Asia hereditary testing market, by disease type, 2015 - 2026 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil hereditary testing market, by disease type, 2015 - 2026 (USD Million)
  • 5.6 Middle East and Africa (MEA)
    • 5.6.1 MEA hereditary testing market, by disease type, 2015 - 2026 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa hereditary testing market, by disease type, 2015 - 2026 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Major Deals & Strategic Alliances Analysis
    • 6.1.1 Merger & acquisition deals
    • 6.1.2 Product launches
    • 6.1.3 Technological & marketing collaboration
  • 6.2 Company Profiles
    • 6.2.1 Myriad Genetics, Inc.
      • 6.2.1.1 Company overview
      • 6.2.1.2 Counsyl, Inc.
      • 6.2.1.2.1 Company overview
      • 6.2.1.3 Financial performance
      • 6.2.1.4 Product benchmarking
      • 6.2.1.5 Strategic initiatives
    • 6.2.2 Invitae Corporation
      • 6.2.2.1 Company overview
      • 6.2.2.2 Financial performance
      • 6.2.2.3 Product benchmarking
      • 6.2.2.4 Strategic initiatives
    • 6.2.3 Illumina, Inc.
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial performance
      • 6.2.3.3 Product benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Natera Inc.
      • 6.2.4.1 Company overview
      • 6.2.4.2 Financial performance (Novartis AG)
      • 6.2.4.3 Product benchmarking
      • 6.2.4.4 Strategic initiatives
    • 6.2.5 Laboratory Corporation of America Holdings
      • 6.2.5.1 Company overview
      • 6.2.5.1.1 Sequenom
      • 6.2.5.2 Financial performance
      • 6.2.5.3 Financial performance
      • 6.2.5.4 Product benchmarking
      • 6.2.5.5 Strategic initiatives
    • 6.2.6 F. Hoffmann-La Roche Ltd
      • 6.2.6.1 Company overview
      • 6.2.6.2 Ariosa Diagnostics
      • 6.2.6.3 Financial performance
      • 6.2.6.4 Product benchmarking
      • 6.2.6.5 Strategic initiatives
    • 6.2.7 Quest Diagnostics Incorporated
      • 6.2.7.1 Company overview
      • 6.2.7.2 Financial Performance
      • 6.2.7.3 Product Benchmarking
      • 6.2.7.4 Strategic initiatives
    • 6.2.8 CooperSurgical, Inc.
      • 6.2.8.1 Company overview
      • 6.2.8.1.1 Genesis Genetics
      • 6.2.8.1.2 Reprogenetics
      • 6.2.8.2 Financial performance
      • 6.2.8.4 Financial performance
      • 6.2.8.5 Product benchmarking
      • 6.2.8.6 Strategic initiatives
    • 6.2.9 Agilent Technologies, Inc.
      • 6.2.9.1 Company overview
      • 6.2.9.2 Financial performance
      • 6.2.9.3 Product benchmarking
      • 6.2.9.4 Strategic initiatives
    • 6.2.10 Thermo Fisher Scientific, Inc.
      • 6.2.10.1 Company overview
      • ?6.2.10.1.1 Life Technologies Corp.
      • 6.2.10.2 Financial performance
      • 6.2.10.3 Product benchmarking
      • 6.2.10.4 Strategic initiatives
    • 6.2.11 Twist Bioscience
      • 6.2.11.1 Company overview
      • 6.2.11.2 Financial performance
      • 6.2.11.3 Product benchmarking
      • 6.2.11.4 Strategic initiatives
    • 6.2.12 Sophia Genetics
      • 6.2.12.1 Company overview
      • 6.2.12.2 Financial performance
      • 6.2.12.3 Product benchmarking
      • 6.2.12.4 Strategic initiatives
    • 6.2.13 Fulgent Genetic, Inc.
      • 6.2.13.1 Company overview
      • 6.2.13.2 Financial performance
      • 6.2.13.3 Product benchmarking
      • 6.2.13.4 Strategic initiatives
    • 6.2.14 Medgenome
      • 6.2.14.1 Company overview
      • 6.2.14.2 Financial performance
      • 6.2.14.3 Product benchmarking
    • 6.2.15 CENTOGENE N.V.
      • 6.2.15.1 Company overview
      • 6.2.15.2 Financial performance
      • 6.2.15.3 Product benchmarking
      • 6.2.15.4 Strategic initiatives